suggests that concerns of effects on steroid hormones and vitamin E levels are more theoretical than real.
L ow-density lipoprotein cholesterol (LDL-C) is one of the most important causal risk factors for atherosclerotic disease. Primary and secondary prevention studies have shown that lowering LDL-C significantly reduces the risk of cardiovascular morbidity and mortality. Intensive statin therapy compared with moderate statin therapy incrementally reduces LDL-C, progression of coronary atherosclerosis, and rates of cardiovascular events. 1, 2 Because cholesterol is needed for adrenal and gonadal steroid hormone biosynthesis, vitamin transport, and cell membrane function, there is a theoretical concern that very low levels of LDL-C achieved with intensive lipid-lowering therapy may lead to adverse effects because of reduced delivery of free intracellular cholesterol. Some reassurance is provided by people with genetic variants that lead to lifelong reduction in LDL-C levels; such individuals appear healthy and have a low incidence of cardiac events. 
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In this issue of Circulation Research, Blom et al 4 explored the safety of very low levels of LDL-C induced by evolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9). The authors thoroughly investigated its effects on steroid hormone and vitamin E levels. In a phase 3, double-blind, randomized, placebo-controlled trial of 901 patients with LDL-C ≥75 mg/dL and risk factors for cardiovascular disease, participants were randomized to monthly subcutaneous evolocumab or placebo for 52 weeks. 5 Steroid hormone and vitamin E levels were measured at baseline and 52 weeks. Cortisol and adrenocorticotropic hormone concentrations were assayed to monitor adrenal steroidogenesis. Estradiol in women and testosterone in men were measured to determine the effect on gonadal steroid synthesis. The investigators measured plasma vitamin E concentrations in all patients, and they measured serum, lipoprotein, and red cell membrane vitamin E concentrations in a subset of 100 study participants.
The investigators found an ≈60% reduction in LDL-C in patients treated with evolocumab when compared with patients treated with placebo. Importantly, 87% of evolocumabtreated patients attained LDL-C levels <40 mg/dL compared with only 2% of subjects treated with placebo. Among patients treated with evolocumab, ≈40% achieved LDL-C levels <15 mg/dL. Evolocumab-treated patients did not have a decrease in cortisol, and there were no significant decreases in testosterone or estradiol levels despite robust reductions in LDL-C levels. Moreover, subgroup analysis in the evolocumab-treated patients who achieved LDL-C levels <15 mg/dL showed no decrease in adrenal or gonadal steroid hormone levels. No decreases in red cell or plasma vitamin E levels were seen.
Very low levels of LDL-C have been previously reported to be safe and beneficial in observational analyses from clinical trials. A post hoc analysis of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial found lower rates of major cardiac events in patients who achieved LDL-C <40 mg/dL than in patients with LDL-C >60 mg/dL. 6 Importantly, LDL-C <40 mg/dL was found to be safe and well tolerated. Similarly, in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), among patients treated with rosuvastatin, attainment of LDL-C <50 mg/dL compared with LDL-C >50 mg/ dL was associated with a lower risk of cardiovascular events without significant differences in safety. 7 Ezetimibe, a nonstatin drug that decreases intestinal absorption of cholesterol, also lowers LDL-C. In a recent randomized trial of patients with acute coronary syndromes, a combination of ezetimibe and simvastatin resulted in low LDL-C levels (≈50 mg/dL) and reduced risk of subsequent cardiovascular events when compared with simvastatin monotherapy. 8 In addition, in a study by Tsujita et al, 9 the combination of statin and ezetimibe lowered LDL-C levels more and induced greater coronary plaque regression than statin therapy alone.
Despite currently used intensive lipid-lowering therapy, many patients are unable to achieve optimal LDL-C levels, and thus are at an elevated risk of cardiovascular events. PCSK9 inhibition has emerged as a promising strategy to lower LDL-C. PCSK9 is a serine protease that plays an important role in modulating LDL-C levels by targeting LDL-C receptors for lysosomal degradation instead of allowing them to be recycled to the hepatocyte cell surface (Figure) . Anti-PCSK9 monoclonal antibodies bind to PCSK9 and inhibit its interaction with LDL-C receptors, thus increasing the expression of LDL-C receptors on the hepatocyte cell surface, resulting in enhanced LDL-C clearance from the circulation. In
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Low Cholesterol, Steroid Hormones, and Vitamin Eseveral phase 2/3 trials, PCSK9 inhibitors have been found to further decrease LDL-C by 50% to 70% across various patient populations when administered as monotherapy or on a background of other lipid-lowering therapies. [10] [11] [12] [13] These trials have demonstrated good tolerability and a low rate of significant adverse effects when compared with placebo, even at very low LDL-C levels.
Several studies have investigated the effects of statins on adrenal and gonadal steroid hormone synthesis and have shown no significant effect. 14 The importance of LDL-receptormediated uptake for delivery of cholesterol for steroid hormone production has been investigated in animals and humans. LDL-receptor double-knockouts have no measurable impact on adrenal steroid hormone synthesis. 15 Furthermore, patients with heterozygous familial hypercholesterolemia treated with statins have normal steroid hormone levels despite reduced delivery of free cholesterol through LDL-receptor-mediated endocytosis. The findings discussed by Blom et al 4 in this welldone mechanistic study are consistent with earlier reports from smaller clinical studies. These findings suggest that the synthesis of steroid hormones is not significantly dependent on LDL-receptor-mediated uptake of exogenous cholesterol. The supply of free cholesterol through alternative pathways such as de novo synthesis, reverse cholesterol transport, mobilization of stored cholesteryl esters, and intestinal absorption is sufficient for production of steroid hormones.
Vitamin E is lipid soluble with antioxidant properties. Vitamin E deficiency leads to neuromuscular disorders, neuropathy, and hemolysis. Patients with abetalipoproteinemia, a rare genetic disorder, have very low LDL-C levels and low levels of fat soluble vitamins including vitamin E. Patients with this disorder are not able to make lipoproteins needed for transport and absorption of fat soluble vitamins. Thus, there arose a theoretical concern that very low LDL-C levels induced by pharmacotherapy can cause vitamin E deficiency. Importantly, PCSK9 inhibition is mechanistically different from the defect in abetalipoproteinemia. PCSK9 inhibitors do not decrease synthesis of lipoproteins needed for absorption and transport of vitamin E. Therefore, it is in fact not surprising that red cell vitamin E levels were unchanged in evolocumab-treated patients. Studies have shown no decrease in vitamin E with statin therapy. Previous studies examining the effect of lipid-lowering therapy on steroid hormones and vitamin E are limited by small sample size. In addition, there is an under-representation of patients with very low LDL-C levels. The study by Blom et al 4 is the first to explore in depth the effect of PCSK9 inhibitors on steroid hormone and vitamin E levels, and it suggests that pharmacologically lowering LDL-C to very low levels, even to LDL-C levels <15 mg/dL, seems safe. This study, however, was only a year in duration and may not have been long enough to detect subtle adverse effects. For example, the findings may not apply to a very young patient with familial hypercholesterolemia started on therapy at an early age.
The Improved Reduction of Outcomes: Vytorin Efficacy International Trial-Thrombolysis in Myocardial Infarction 40 (IMPROVE IT-TIMI 40) trial reinforces the concept that lower LDL-C is better, and it suggests that this benefit is true not only for statins. Likely, most clinicians will find IMPROVE IT-TIMI 40 data compelling and titrate lipid-lowering therapy to target LDL-C levels to 50 mg/dL in high-risk patients. Whether even lower levels of LDL-C with PCSK9 inhibition will further decrease cardiovascular events is being tested in 16 These large studies will also offer a comprehensive assessment of the long-term safety of PCSK9 inhibitors. Until then, the present timely analysis provides reassuring safety data about low levels of LDL-C achieved by PCSK9 inhibition and strongly Figure. The schematic demonstrates the mechanism of low-density lipoprotein (LDL) cholesterol reduction by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, the sources of hepatic cholesterol, and the role of cholesterol as a precursor for the synthesis of various metabolites, including steroid hormones. LDL-R indicates LDL receptor; and VLDL, very lowdensity lipoprotein.
